Intake of 25-Hydroxyvitamin D3 Reduces Duration and Severity of Upper Respiratory Tract Infection: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study.

OBJECTIVES: This study aimed to assess the effect of 25-hydroxyvitamin D3 (25OHD) which is a hydroxide of vitamin D3 ingestion on upper respiratory tract infection (URTI). DESIGN AND SETTING: A prospective, randomized, double-blind, placebo-controlled study was performed from December 2015 to September 2016 in the Nihonbashi Egawa Clinic, Kei Medical Office TOC Building Medical Clinic, and Medical Corporation Kaiseikai Kita-Shinyokohama Medical Clinic, in Japan. PARTICIPANTS: Four hundred twenty eight participants aged 45-74 years were screened by their serum 25-hydoroxyvitamin D concentration. INTERVENTION: The participants were randomized to either 25OHD (10 µg/day) or placebo capsule, daily, for 16 consecutive weeks. MEASUREMENTS: The primary outcome measure was the incidence proportion of URTI, and the secondary outcome measures were the physical severity score, the quality-of-life (QOL) score, the duration of URTI, and the incidence proportion of new URTI events every four weeks. Data were collected using cold diary Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) during the intervention. RESULTS: Of 428 participants screened, 252 with serum 25-hydroxyvitamn D levels were deficient or insufficient (75 nmol/L or less) were enrolled in this study. Of these, 105 placebo and 110 25OHD group subjects completed the study. For the incidence proportion of URTI, no effect of 25OHD intake was observed. On the other hand, the duration of URTI was shorter in the 25OHD (P = 0.061) compared to placebo. For the incidence proportion of URTI every four weeks, the incidence of new URTI was decreased in both groups over the time of intake. However, when the 25OHD and the placebo were compared, a decrease in the incidence proportion of URTI was seen earlier in the 25OHD. When the total physical severity score and the total QOL score during the study were assessed, they both were significantly improved in the 25OHD compared to placebo. CONCLUSIONS: The intake of 25OHD may reduce the duration of URTI, the physical severity, and the QOL when suffering from URTI.

Isolation of a novel ras-recision gene that is induced by hydrogen peroxide from a mouse osteoblastic cell line, MC3T3-E1.

Hydrogen peroxide appears to mediate growth factor actions, and it inhibits DNA synthesis in normal mouse osteoblastic cells (MC3T3-E1) at non-toxic doses. However the sensitivity of cells to H2O2 is greatly decreased in their ras-transformants. To understand the molecular basis of this sensitivity to H2O2, we attempted to identify H2O2-inducible cDNA clones from MC3T3 cells by differential screening of cDNA libraries, and one of such genes, named HIC-53, was isolated. The level of HIC-53 mRNA was moderately increased by H2O2 as well as by calcium ionophore or dexamethasone, but was not increased by the addition of serum, tumor promoting phorbol ester, or epidermal growth factor. Among mouse organs, HIC-53 mRNA levels were higher in the kidney and lung, but were almost undetectable in the brain, heart, bone, muscle or spleen. In MC3T3 cells transformed with v-Ki-ras, the HIC-53 mRNA level was markedly decreased, and effect of H2O2 was abolished. Although the biological function of HIC-53 is unknown at present, the predicted amino acid sequence exhibited some similarity with bovine cardiac Na+/Ca+ exchanger. The nucleotide sequence of HIC-53 cDNA showed no significant similarity with other known gene sequences.